Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

2.1%

14 terminated/withdrawn out of 673 trials

Success Rate

89.1%

+2.6% vs industry average

Late-Stage Pipeline

16%

105 trials in Phase 3/4

Results Transparency

3%

3 of 114 completed trials have results

Key Signals

146 recruiting3 with results8 terminated6 withdrawn

Enrollment Performance

Analytics

N/A
176(41.6%)
Phase 2
121(28.6%)
Phase 4
63(14.9%)
Phase 3
42(9.9%)
Phase 1
17(4.0%)
Early Phase 1
4(0.9%)
423Total
N/A(176)
Phase 2(121)
Phase 4(63)
Phase 3(42)
+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (673)

Showing 20 of 673 trials
NCT07643922Not ApplicableNot Yet Recruiting

Endovascular Therapy for Cerebral Vasospasm After Aneurysmal Subarachnoid Hemorrhage

Role: collaborator

NCT07645846Phase 2Not Yet Recruiting

Neoadjuvant Docetaxel, Cisplatin, and Dual Immunotherapy for Sinonasal Carcinoma

Role: collaborator

NCT07642427Phase 4Not Yet Recruiting

Early Prophylactic Aspirin for Aneurysmal Subarachnoid Hemorrhage

Role: collaborator

NCT07620626Recruiting

Real-World Study of Woven EndoBridge for Intracranial Aneurysm Treatment

Role: collaborator

NCT05606315Phase 4Suspended

RemImazolam Besylate for ICU-sedation in Patients With Mechanical Ventilation After Oral and Maxillofacial Surgery

Role: lead

NCT07636486Phase 2Not Yet Recruiting

Luspatercept vs Epoetin in Treating Poor Erythroid Engraftment for Hematological Malignancies

Role: lead

NCT07635485Not ApplicableNot Yet Recruiting

VA Induction and Bridging Transplantation for Hypoplastic/Secondary AML

Role: collaborator

NCT07637448Phase 2Recruiting

EGFR-TKIs Plus PD-1 in EGFR-Mutant Advanced NSCLC

Role: lead

NCT07604688Recruiting

Multicenter Registry Study of Patients With Intracranial Dural Arteriovenous Fistulas in China

Role: collaborator

NCT07627347Not ApplicableRecruiting

Efficacy and Safety of Anlotinib Combined With Bemocizumab for Neoadjuvant Therapy of Esophageal Squamous Cell Carcinoma(ESCC)

Role: lead

NCT07622667Recruiting

Correlation Analysis of Gene Characteristics of Malignant Tumors With Prognosis

Role: lead

NCT07622693Active Not Recruiting

Beta-Blockers on Neoadjuvant Immunochemotherapy for Hypertensive Patients With Gastric Cancer

Role: lead

NCT05507632Phase 2Active Not Recruiting

Donafenib Plus Sintilimab in Combination With TACE in Patients With Unresectable Hepatocellular Carcinoma

Role: lead

NCT07608120Not ApplicableRecruiting

Electrolyte Beverage Combined With Polyethylene Glycol for Colonoscopy Bowel Preparation

Role: lead

NCT05129904Active Not Recruiting

Precise Profiling of Liver Disease Patients With DPMAS Therapy, Treating Optimal Patients and Achieving Hard Endpoint (PADSTONE Study)

Role: lead

NCT07604311Phase 4Not Yet Recruiting

Efficacy and Safety of Nefecon on Prevention of Relapse of IgA Nephropathy: a Randomized, Double-blinded, Placebo-Controlled Trial

Role: lead

NCT07603349Phase 2Not Yet Recruiting

Adaptive Adjuvant Therapy After Neoadjuvant Therapy and Gastrectomy for Gastric or Gastroesophageal Junction Adenocarcinoma

Role: lead

NCT07604298Not Yet Recruiting

Efficacy and Safety of Indobufen, Aspirin, Cilostazol and Clopidogrel in the Treatment of Ischemic Stroke

Role: lead

NCT05928299Completed

Integrative Multi-Omics Testing for Immunotherapy Response in Non-Small Cell Lung Cancer

Role: lead

NCT05788029Not ApplicableEnrolling By Invitation

Comparing Laparoscopic and Open Pancreaticoduodenectomy for Nonpancreatic Periampullary Adenocarcinomas

Role: collaborator